Protalix BioTherapeutics PLX
NYSE PLX
$2.57 -0.07 (-2.65%)
As of: Oct 21, 2026 · 3:59 PM EDT

Protalix BioTherapeutics (PLX) Non Operating Interest Expenses (2024 - 2025)

Updated

Protalix BioTherapeutics' Non Operating Interest Expenses was $6,000 in Q1 2025, down 85.4% from the prior quarter.

Analysis

Protalix BioTherapeutics (PLX) Non Operating Interest Expenses (2024 - 2025) Analysis & Trends

On a trailing twelve-month basis, Protalix BioTherapeutics' Non Operating Interest Expenses was $686,000 through Mar 31, 2025; for FY2024, it came in at $1.06 million, down 66.6% from FY2023.

  • In earlier years, Non Operating Interest Expenses was $3.18 million in FY2023.
  • Per Business Quant data, PLX's Non Operating Interest Expenses in the three quarters before Q1 2025 was $41,000 (Q4 2024), $260,000 (Q3 2024) and $379,000 (Q2 2024).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 281.00 Mn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 462.00 Mn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 435.00 Mn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 673.00 Mn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 247.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Protalix BioTherapeutics 207.16 Mn 55.78 Mn 12.13 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 6,000.00
Dec 31, 2024 41,000.00
Sep 30, 2024 260,000.00
Jun 30, 2024 379,000.00
API Access

Protalix BioTherapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=PLX&period=max&api_key=YOUR_API_KEY